Journal article · 2025 · Open access
Reanalysis of in vivo drug synergy validation study rules out synergy in most cases
Nature Communications, 16(1), 8534 · Published 30 September 2025 · DOI 10.1038/s41467-025-62617-w
In brief
“Reanalysis of in vivo drug synergy validation study rules out synergy in most cases” is a 2025 journal article by Olaf van Tellingen and Renée X. de Menezes, published in Nature Communications. OpenAlex counts 5 citations as of 15 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Communications.
- Citations
- 5
- Most cited in
- 2026 (4)
- Field-weighted impact
- 1.43
- References
- 13
- Authors
- 2
Abstract
Narayan et al. 1 described the development of an in silico platform (“Drug Atlas”) to predict synergistic drug combinations and claimed successful in vivo validation in five models. Demonstrating the impact of a given drug in in vivo models is challenging because effect sizes are often small 2 . Because of the inherent variability in tumor outgrowth in vivo, achieving adequate statistical power requires sufficiently sized groups. As the experimental complexity increases, for example, when assessing combination effects, the minimum required group size also increases. A statistically sound distinction between additive and synergistic drug effects requires even larger datasets, as do comparisons across multiple drug combinations of drugs.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
van Tellingen, O., & de Menezes, R. X. (2025). Reanalysis of in vivo drug synergy validation study rules out synergy in most cases. Nature Communications, 16(1), 8534. https://doi.org/10.1038/s41467-025-62617-w
MLA 9
van Tellingen, Olaf, and Renée X. de Menezes. “Reanalysis of in vivo drug synergy validation study rules out synergy in most cases.” Nature Communications, vol. 16, no. 1, 2025, p. 8534. https://doi.org/10.1038/s41467-025-62617-w.
Chicago
van Tellingen, Olaf and Renée X. de Menezes. 2025. “Reanalysis of in vivo drug synergy validation study rules out synergy in most cases.” Nature Communications 16 (1): 8534. https://doi.org/10.1038/s41467-025-62617-w.
Harvard
van Tellingen, O. and de Menezes, R. X. (2025) ‘Reanalysis of in vivo drug synergy validation study rules out synergy in most cases’, Nature Communications, 16(1), p. 8534. doi:10.1038/s41467-025-62617-w.
IEEE
O. van Tellingen and R. X. de Menezes, “Reanalysis of in vivo drug synergy validation study rules out synergy in most cases,” Nature Communications, vol. 16, no. 1, p. 8534, 2025, doi: 10.1038/s41467-025-62617-w.
BibTeX
@article{vantellingen2025reanalysis,
title = {{Reanalysis of in vivo drug synergy validation study rules out synergy in most cases}},
author = {van Tellingen, Olaf and de Menezes, Renée X.},
journal = {Nature Communications},
year = {2025},
volume = {16},
number = {1},
pages = {8534},
doi = {10.1038/s41467-025-62617-w},
url = {https://doi.org/10.1038/s41467-025-62617-w}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- drug synergy
- drug combination effects
- in vivo validation
- statistical power
- sample size requirements
Work with this paper
Most-cited papers in Pharmacology, Toxicology and Pharmaceutics
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingOleg Trott, Arthur J. Olson · Journal of Computational Chemistry · 2009 · 39,860 citations
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityGarrett M. Morris, Ruth Huey, William Lindstrom and 4 more · Journal of Computational Chemistry · 2009 · 26,508 citations
- Development and testing of a general amber force fieldJunmei Wang, Romain M. Wolf, James W. Caldwell and 2 more · Journal of Computational Chemistry · 2004 · 20,080 citations
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy and 1 more · Advanced Drug Delivery Reviews · 2001 · 19,638 citations
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesAntoine Daina, Olivier Alain Michielin, Vincent Zoete · Scientific Reports · 2017 · 19,557 citations
All highly cited Pharmacology, Toxicology and Pharmaceutics papers
Questions about this paper
How do I cite this paper in APA style?
van Tellingen, O., & de Menezes, R. X. (2025). Reanalysis of in vivo drug synergy validation study rules out synergy in most cases. Nature Communications, 16(1), 8534. https://doi.org/10.1038/s41467-025-62617-w
How many times has this paper been cited?
5 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Nature Communications.
Who wrote this paper?
Olaf van Tellingen, Renée X. de Menezes.
What is the DOI of this paper?
10.1038/s41467-025-62617-w. The permanent link is https://doi.org/10.1038/s41467-025-62617-w.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.